Abstract: The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: Aspects of the disclosure provide a stackable and modular battery energy storage system. An example energy storage system may include a plurality of stacked containers, each of the plurality of containers includes a housing having an upper face and a lower face; the lower face of a second container is disposed on the upper face of a first container; at least the second container includes a battery pack within the housing; at least one electrical interface situated on the lower face of the second container is connected to at least one electrical interface situated on the upper face of the first container; and at least one flow interface situated on the lower face of the second container is connected to at least one flow interfaces situated on the upper face of the first container.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues and optionally Ab species to diagnose a subject, guide treatment decisions, and select subjects for clinical trials.

Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R-tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: This invention relates to epitope binding agents that specifically bind to tau and methods of use thereof. The disclosure provides immunoassays, kits, and pharmaceutical compositions which include an epitope binding agent that specifically bind to tau. The disclosure provides methods of reducing the spread of tau aggregates and methods of reducing a tauopathy-related pathology.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.